Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Stopped early · Phase 1
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
Key facts
- Study ID
- NCT00096304
- Run by
- Medical University of South Carolina
- People needed
- 36
- Starts
- 2004-06-08
- Expected to finish
- 2007-11-30
- Last updated by the study team
- 2018-04-10
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.